Innovative Oral Therapies Syntis Bio is advancing a pipeline of oral therapies engineered to leverage the small intestine’s biology, presenting significant opportunities for partnerships or licensing deals with pharmaceutical companies seeking novel treatment platforms for metabolic and gastrointestinal conditions.

Strong Clinical Progress With its lead program, SYNT-101, in clinical-stage development for obesity mimicking gastric bypass outcomes, Syntis offers a compelling product development story that can attract investment, licensing, or co-development collaborations from biotech and pharma firms focused on obesity and metabolic disorders.

Strategic Funding & Support Securing substantial Series A funding of over $38 million along with $5 million in non-dilutive NIH grants positions Syntis as a promising partner for investors and research collaborators interested in groundbreaking biotechnologies addressing large markets.

Leadership & Talent Growth Recent high-profile executive hires, including a Chief Development Officer and Chief Business Officer, demonstrate Syntis Bio’s focus on strengthening leadership to accelerate market entry, representing opportunities for strategic alliances and business development engagement around upcoming clinical milestones.

Market Expansion Potential Given the company’s focus on accessible, effective treatments for common conditions like obesity, there are opportunities to collaborate on distribution, commercialization, and real-world evidence generation with health system partners and global health stakeholders aiming to expand treatment options.